268
Participants
Start Date
August 31, 2025
Primary Completion Date
September 15, 2028
Study Completion Date
December 23, 2028
GB08
"In Phase II trial, eligible PGHD patients will receive GB08 0.4mg/kg, 0.8mg/kg, or 1.2mg/kg subcutaneous injection, once a week for 24 weeks.~In Phase III trial, the individuals will receive GB08 subcutaneous injection, once a week for 52 weeks. The dose of GB08 at this stage will be determined by the outcomes of Phase II."
Norditropin NordiFlex
Norditropin NordiFlex 0.035 mg/kg subcutaneous injection, daily, for 24 weeks (Phase II) or 52 weeks (Phase III)
The First Hospital of Jilin University, Changchun
Suzhou University Children's Hospital, Suzhou
Linyi Maternal and Child Health Hospital, Linyi
Zhejiang Provincial People's Hospital, Hangzhou
Children's Hospital of Zhejiang University School of Medicine, Hangzhou
Ningbo Women's and Children's Hospital, Ningbo
Jiangxi Children's Hospital, Nanchang
Pingxiang Maternal and Child Health Hospital, Pingxiang
Xiamen Maternal and Child Health Hospital, Xiamen
Wuhan Children's Hospital, Wuhan
The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang
Nanyang Central Hospital, Nanyang
The First Affiliated Hospital of Nanyang Medical College, Nanyang
Chengdu Women's and Children's Central Hospital, Chengdu
Meishan People's Hospital, Meishan
The Second People's Hospital of Yibin, Yibin
Shenzhen Kexing Pharmaceutical Co., Ltd.
NETWORK